DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Account Payables
Amounts the company owes suppliers for goods and services received.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 118.5% from a year ago
Account payables stood at $3.29M at the end of Q1 FY2026, up 118.5% from a year earlier and up 123.3% from the prior quarter. Over 3 fiscal years it compounded at +26.2% a year.
Context
- Account payables amounted to 6.2% of total assets at the end of Q1 FY2026, up 2.3 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +118.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.48M USD
- Year-over-year change
- +56.9%
- 4-year CAGR
- +30.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.48M | +56.9% |
| FY2024 | 2024-12-31 | 940K | +1.5% |
| FY2023 | 2023-12-31 | 926K | +26.2% |
| FY2022 | 2022-12-31 | 734K | +44.2% |
| FY2021 | 2021-12-31 | 509K | — |
Account Payables vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 account payables of $3.29M is the 4th highest of the 7 companies compared; the peer median is $3.54M.
- Its year-over-year change of +118.5% is the highest of 7, against a peer median of -18.0%.
- Account payables amounts to 6.2% of total assets for DMAC, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $11.81M | +8.9% | +6.1% | 1.0% | |
| Mar 2026 | $8.39M | -33.7% | +5.5% | 2.3% | |
| Mar 2026 | $4.01M | +66.9% | +4.2% | 1.0% | |
| Mar 2026 | $3.29M | +118.5% | +26.2% | 6.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $3.07M | -23.1% | +5.8% | 0.8% |
| Mar 2026 | $2.59M | -17.0% | -32.4% | 0.9% | |
| Mar 2026 | $1.01M | -18.9% | -29.1% | 1.6% | |
| Peer median (excluding DMAC) | $3.54M | -18.0% | +4.9% | 1.0% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.